You are here: Industry Insights > Galcanezumab

News List

Galcanezumab Can Cut Frequency of Cluster Headache Attacks drugs
July 11, 2019
Galcanezumab can reduce the frequency of episodic cluster headache attacks, according to a study published in the issue of the New England Journal of Medicine.
Marking a bumper month for Committee for Medicinal Products for Human Use (CHMP) decisions, 13 medicines have been put forward for approval in the region, including three orphan medicines. pharmatimes
September 27, 2018
Marking a bumper month for Committee for Medicinal Products for Human Use (CHMP) decisions, 13 medicines have been put forward for approval in the region...
Mixed trial results for Lilly’s headache drug galcanezumab pharmatimes
July 13, 2018
Lilly has reported mixed trial data for its experimental therapy galcanezumab, showing efficacy in patients with episodic cluster headaches but failing in those with chronic cluster headache.
Lilly's Galcanezumab Meets Primary Endpoint americanpharmaceuticalreview
May 18, 2018
Eli Lilly and Company announced galcanezumab met its primary endpoint in a Phase 3 study of patients with episodic cluster headache,
FDA Accepts BLA to Review Galcanezumab for Migraine americanpharmaceuticalreview
December 12, 2017
Eli Lilly and Company announced the U.S. Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) to review galcanezumab for the prevention of migraine in adults
Lilly Announces Positive Results for Three Phase 3 Studies of Galcanezumab lilly
May 15, 2017
Eli Lilly announced galcanezumab, an investigational treatment for the prevention of episodic and chronic migraine, met its primary endpoint in three Phase 3 studies.